Alithea Biotechnology develops Data-driven solutions for modern immunotherapies. The company combines Immunopeptidomics, mass spectrometry and AI-based bioinformaticsto precisely identify therapy-relevant target structures.

The core of the innovation is a Cloud-based HLA peptide databaseThis helps to predict the efficacy and safety of new immunotherapies at an early stage. This shortens development times and reduces risks in preclinical phases.